The Latest

• August 20, 2020

  By Charleston Lim

  BioMarin Pharmaceuticals' Stock Price Falls After FDA Rejects Treatment Application

  BioMarin Pharmaceuticals' shares fell more than 31 percent Wednesday after the FDA called for more data about its hemophilia therapy.

  

  BioMarin Pharmaceuticals' shares fell more than 31 percent Wednesday after the FDA called for more data about its hemophilia therapy.